PBCNet:Computing Relative Binding Affinity of Ligands to a Receptor Based on a Pairwise Binding Comparison Network for Lead Optimization

24 April 2023, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Structure-based lead optimization is an open challenge in drug discovery, which is still largely driven by hypotheses and depends on the experience of medicinal chemists. We here propose a pairwise binding comparison network (PBCNet) based on physics-informed graph attention mechanism, specifically tailored for ranking relative binding affinity among congeneric ligands. Benchmarking on two held-out sets (provided by Schrödinger, Inc. and Merck KGaA) containing over 460 ligands and 16 targets, PBCNet demonstrated significant advantages in terms of both prediction accuracy and computational efficiency. Equipped with a fine-tuning operation, the performance of PBCNet reaches that of Schrödinger's FEP+, which is much more computationally intensive and requires significant expert intervention. A further simulation-based experiment showed that active learning-optimized PBCNet may accelerate lead optimization campaigns by 30%. Finally, for the convenience of users, a web service (https://pbcnet.alphama.com.cn/index) for PBCNet is established to facilitate complex relative binding affinity prediction through an easy-to-operate graphical interface.

Keywords

Structure-based lead optimization
Structure-based drug design

Supplementary materials

Title
Description
Actions
Title
Supplementary information
Description
Supplementary information. Some illustrative tables and images are provided in this document.
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.